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one state to another. Depending on the purpose, the color of the parallelograms
indicates the categories of a chosen cycle or could refer to additional attributes of
the patients like age or sex. RESULTS: State probability and survival curves merely
show specific aggregates of the data while classic Markov trace visualizations with
for example bubble diagrams do not visualize data in a sense that would facilitate
a detection of proportions and trends. Applying Parallel Sets to analyze Markov
models provides an interactive visualization technique where changing the refer-
ence Markov cycle is as easy as highlighting particular dimensions, thus enabling
the exploration of the progress of patient cohorts with certain characteristics
through the model. CONCLUSIONS: Model development always requires thorough
analysis of its structure, behavior and results. Parallel Sets enable an intuitive and
efficient visualization technique for presentation purposes as well as exploratory
analysis.
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OBJECTIVES: Crohn’s disease (CD) is a relapsing remitting inflammatory disease
affecting the gastrointestinal tract. Previous economic evaluations in CD have fo-
cussed on single treatment comparisons within the treatment pathway. This proj-
ect aimed to develop a model capturing lifetime costs and utilities throughout the
entire treatment pathway. METHODS: A treatment sequence model was adapted
from an earlier CD model by including the option to change treatments as patients
stop responding. A Markov structure was used with five health-states: full-, partial-
and no-response, surgery and death. Transition probabilities and survival rates
were derived from previous analyses with separate transition matrices used for
standard care and anti-TNF-s. The model allows for 11 treatment stages (each
with induction and maintenance phases) to be evaluated. Patients failing in induc-
tion progress to the next stage, if failing in maintenance they return to the induc-
tion treatment from that stage unless it is the same as the maintenance treatment.
Surgery can be included as a separate treatment stage, although patients can re-
ceive surgery at any time. Costs were taken from published sources, and utilities
from previous analyses. Limitations of available contemporary data and reporting
of modelling methods posed challenges for model development; in particular the
lack of data on the efficacy of combination treatment and probabilities of sustained
response on anti-TNF- therapies. RESULTS: In a patient cohort (mean age 35),
lifetime costs and QALYs (LYs) were £169,560 and 14.85 (20.97) for a treatment
pathway where patients initiated therapy with steroids azathioprine followed by
azathioprine maintenance, progressed through more intensive steroid induction,
available anti-TNF-s and surgery, ultimately becoming treatment refractory.
CONCLUSIONS: This model represents an advance in economic evaluation of CD,
allowing lifetime evaluation of treatment strategies in a complex treatment area.
Further research into the natural history of CD would improve the potential for
robust economic evaluation.
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OBJECTIVES: To identify the meaning of descriptors patients use to describe the
quality and severity of their pain by mapping word clusters that patients identify as
synonyms for the same pain sensation.METHODS: Subjects were recruited by web
posting and telephone screening. Those self-reporting active treatment for Mi-
graine or Low Back Pain (LBP) were scheduled for in-person interviews using card
sort exercises with 93 different pain descriptors to identify those each subject
commonly used to describe the pain associated with their condition, and to iden-
tify pairs of descriptors that describe the same pain. Network maps that dia-
grammed patient identified equivalences between descriptors were created for
each condition using Netdraw (Borgatti 2002) and then compared. RESULTS: Sub-
jects ranged between 19 and 70 years (mean age of 41). The majority (73%) was
female, 65% were working full or part time, and 59% were Caucasian. Migraine
patients identified more descriptive synonyms to describe their pain (10% of all
identified synonym pairs) than the LBP group (6%). For the Migraine group, most
words used synonymously formed a single large cluster of connections. For the LBP
group two main clusters of descriptors emerged, differentiating low-intensity and
high-intensity pain. Patients in both groups tended to identify STIFFNESS-TIGHT,
ACHING-HURTING, RADIATING-SHOOTING and PULSATING-PULSING-THROB-
BING as synonymous. LBP patients also associated RADIATING with movement
(SPREADING/PENETRATING) and thermal (HOT) descriptors, while Migraine pa-
tients tended to use it interchangeably with PIERCING. Migraine patients described
TIGHT as equivalent with SQUEEZING/CRUSHING, while LBP patients associated it
with PULLING/TENSION. For LBP patients, SPREADING was closely associated with
PENETRATING/RADIATING/SHOOTING, while for Migraine patients it was linked
closely to THROBBING/GNAWING/FLASHING.CONCLUSIONS:While some descrip-
tors were used to convey a more consistent meaning across groups, other descrip-
tors demonstrated condition-specific meaning. These findings emphasize the im-
portance of context of use when using pain as a study endpoint.
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OBJECTIVES: The purpose of this analysis was to develop a mapping algorithm to
estimate EQ-5D utilities based on the 25-item National Eye Institute Visual Func-
tioning Questionnaire (VFQ-25), a patient-reported outcome measure developed to
evaluate vision-specific functioning. METHODS: The dataset comprised 951 paired
EQ-5D/VFQ-25 observations from 344 patients in RESTORE, a 12-month, random-
ized, double-masked trial in patients with visual impairment due to diabetic mac-
ular edema. EQ-5D index scores were calculated based on the UK tariff. We evalu-
ated 11 models and 4 separate predictor lists of VFQ-25 subscales to estimate utility
as a function of VFQ-25 score, based on 4 models: Tobit, CLAD (Censored Least
Absolute Deviation), GEE (Generalized Estimating Equation) and reverse two-part
GEE models (which address the strong ceiling effect and left-skewed distribution of
the EQ-5D). Model performance was assessed by ten-fold cross-validation compar-
ing root mean squared error (RMSE), mean absolute error (MAE) and correlation
with EQ-5D score (Spearman R-squared). RESULTS: Mapping results were similar
across all techniques and predictor lists. The reverse two-part GEE model had the
best predictive performance (RMSE 0.199, MAE 0.140) and used fewest predictors,
but correlated relatively weakly with the original EQ-5D results (Spearman
R-squared 0.34). CONCLUSIONS: Mapping VFQ-25 scores to EQ-5D utilities results
in low predictive power independent of the modelling methodology applied. The
difficulties in this mapping exercise are likely the result of the inability of the EQ-5D
to discriminate vision-related activities.
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OBJECTIVES: Regulatory agencies show a growing interest in quantitative models
for risk-benefit assessments to increase decision transparency. Regulators increas-
ingly incorporate patients’ view on benefit-risk tradeoffs but little is known on how
to integrate elicited preferences into the quantitative models. There is little knowl-
edge on how to integrate these preferences with clinical performance data and how
to use knowledge about the uncertainty surrounding both types of parameters
(preference and performance). The objective of this study was to demonstrate how
patient preferences can be integrated in a Bayesian framework for quantitative
benefit-risk assessment. METHODS: An MCDA model was developed that inte-
grates clinical trial data, elicited patient preferences and uncertainty surrounding
these estimates. Stochastic characteristics of preference and drug performance
parameters can be approximated from stated preference studies and performance
data from systematic reviews or RCT’s. Risk and benefit scores of drugs are then
simulated with Monte Carlo methods using approximated distributions. The ac-
ceptability (runs where weighted benefits weighted risks) is calculated. A ‘bene-
fit-risk factsheet’ with acceptability graphs is provided, to facilitate decision mak-
ers in their appraisal. RESULTS: The model was applied to an anti-depressants
case. We included two benefit and one risk criteria. Preference data was derived
from an expert panel and the performance data (pooled odds ratio’s compared to
placebo) were derived from a systematic review. The simulations show all drugs
have high (
1) acceptabilities. The problem is more sensitive to performance in-
formation than to preference information and most sensitive to the adverse events
performance criterion. CONCLUSIONS: Using this MCDA model it is possible to
include patient preference in a quantitative risk-benefit assessment model. The
model allows integration of stochastic uncertainty concerning preference and per-
formance. It demonstrates that comprehensive presentation of data is possible.
We are currently working on applying the model to a case on advanced renal cell
carcinoma.
PRM80
PROPORTIONAL HAZARDS ASSUMPTION AND ITS IMPACT ON RESULTS OF
COST-EFFECTIVENESS ANALYSIS
Pochopien M, Zerda I, Gwiosda B, Plisko R
HTA Consulting, Krakow, Poland
OBJECTIVES: If proportional hazards assumption holds, Cox regression allows for
estimation of treatment effect in the form of hazard ratio. The common practice is
to fit parametric model to control arm, then to apply hazard ratio to predict treat-
ment arm. However proportional hazards assumption is rarely verified. Our aim
was to estimate how proportional hazards assumption may impact
cost-effectiveness. METHODS: Markov model was developed to describe cancer
patients treatment. Health states distinguished in the model were: progression-
free, progression and death. Time to progression and death were obtained from
clinical trials for breast and renal cell cancer and implemented into the model on
the basis of Weibull curves, fitted to data from clinical studies. Calculations were
carried out separately with or without using given hazard parameters. It was as-
sumed that compared interventions differ only in terms of time to progression or
death. All the other parameters were the same for both arms. RESULTS: In case of
renal cell carcinoma bisphosphonates combined with sunitinib were compared
with sunitinib alone. When time to progression differs between interventions the
average time spent by patient in progression-free state was 1.39 vs 0.72 and 2.01 vs
0.72 years with and without proportional hazards assumption, what lead to differ-
ences in QALY of 0.20 and 0.39 respectively. When time to death differs between
interventions the average survival was 5.17 vs 2.65 years and 5.41 vs 2.65 years with
and without proportional hazards assumption and that resulted in differences in
QALY of 1.01 and 1.11.CONCLUSIONS: These results indicate that, taking costs into
account, proportional hazard assumption may have large impact on cost-effective-
ness. Proportional hazards assumption should be always checked and its impact
on obtained results should be estimated in sensitivity analysis.
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